ClouDr Signs Healthcare Cooperation Deal With Shaanxi Pharmaceutical
01:03 AM EST, 01/12/2023 (MT Newswires) -- ClouDr Group (HKG:9955) signed a cooperation deal with Shaanxi Pharmaceutical Holding Group and Shaanxi Pharmaceutical Holding Group Paion Pharmaceutical for
ClouDr Group to Narrow FY22 Loss
08:51 PM EST, 12/05/2022 (MT Newswires) -- ClouDr Group (HKG:9955) is forecasting its adjusted net loss to narrow 21.2% to 34.7% year over year in 2022 to 290 million yuan to 350 million yuan, accord
ClouDr: Expected Improvement in Adjusted Net Loss Due to Strong Business Growth, Cost Controls >9955.HK
ClouDr: Expected Improvement in Adjusted Net Loss Due to Strong Business Growth, Cost Controls >9955.HK
ClouDr Group Sees 2022 Rev CNY2.70B-CNY3.10B, Up 54%-76.5% on Year >9955.HK
ClouDr Group Sees 2022 Rev CNY2.70B-CNY3.10B, Up 54%-76.5% on Year >9955.HK
An Intrinsic Calculation For ClouDr Group Limited (HKG:9955) Suggests It's 29% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of ClouDr Group Limited (HKG:9955) as an investment opportunity by taking the expected future cash flows
Zhiyun Health: interim report 2022
ClouDr Group's Net Loss Narrows in H1
12:33 AM EDT, 08/19/2022 (MT Newswires) -- ClouDr Group's (HKG:9955) loss attributable to equity shareholders for the six months ended June 30 decreased year over year to 1.23 billion yuan ($180.6 mil
Zhiyun Health: interim results announcement for the six months ended June 30, 2022
Zhiyun Health: date of the Board of Directors
ClouDr's Hong Kong IPO Stabilization Ends with No Overallotment; Shares Slump 10%
02:35 AM EDT, 07/29/2022 (MT Newswires) -- ClouDr Group (HKG:9955) said no overallotment option was exercised in its Hong Kong listing and the stabilization period of its initial public offering ended
Loading...
No Stock Yet